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Participants were randomised 1:1 to two sequence groups, via a centralised interactive web response system. There was no predefined randomisation list. Instead, assignment was done dynamically using the minimisation method of Pocock and Simon 6 to reduce the risk of imbalanced treatment sequence assignment in sites and study. In case of a treatment sequence imbalance within the site (or globally if balance was achieved within the site) a new subject was randomised with a probability of 85% to the underrepresented sequence. If sequences were balanced both within the site and globally, a new subject was randomised between sequences using a probability of 50%. Before shipment to investigational sites, each vial of product was covered by a masking system and was packaged in an individual box.
Each vial and box was labelled with a unique identification number and all other useful information for the study except information enabling the identification of the product. Before each course, the hospital pharmacist logged in the interactive web response system and obtained the vial identification numbers for vials to be administered to the subject. The hospital pharmacist finalised the blind aspect of the vial by masking the vials' caps. The products were provided to the investigator with a masking system and infusion lines, ready for intravenous administration with a B-Braun infusion pump (Infusomat Space). The dose and frequency of treatment were maintained at prerandomisation levels. The allowed range was between 1 g/kg over 1 to 3 days and 2 g/kg over 2 to 5 days every 4 to 8 weeks (AE7 days).
The maximum dose and frequency was 2 g/kg every 4 weeks.
After the initiation of the trial, two major modifications were made to the exclusion criteria. Participants who had previously been treated with Kiovig ® could be enrolled, if they had not received Kiovig ® during the last 6 months. Given the half-life of Kiovig ® in adults, this period was considered sufficiently long to limit any potential carryover effect.
The potential risk of acute renal failure and renal monitoring in subjects at risk were addressed by adding a urine protein reagent strip test before the initiation of product administration and at all follow-up visits for subjects with abnormal results for this test at screening or with a glomerular filtration rate (GFR) in the 60 to 80 mL/min/1.73 m 2 range. The exclusion limit for GFR was decreased from 80 to 60 mL/min/1.73m
2 .
An albumin-to-creatinine ratio >30 mg/mmol and a protein-tocreatinine ratio >50 mg/mmol were added as exclusion criteria.
| Participant selection
Adult men and women (≥18 years old) were eligible for inclusion if they 
| Outcome measures
The primary efficacy outcome was the Modified Medical Research
Council (MMRC) sum score of 10 predetermined muscle groups, as described by Cats et al, 7 during the evaluation period. Five muscle groups from the arm and five from the leg were tested (Table 1) . Each muscle group was scored from 0 (paralysis) to 5 (normal strength) and 10 movements were assessed on both sides, resulting in a total score between 0 (complete paralysis) and 100 (full strength).
Secondary efficacy outcomes included the MMRC new 10-sum score developed specifically for this study, the Rasch-built MMRC 10-sum score, 7 the MMRC 14-sum score (Table 1) , grip strength measured with a dynamometer for the most affected hand and disability in daily activities, as assessed with the inflammatory neuropathy course and treatment (INCAT) disability score 8 
as used in MMN by
Stangel et al. 9 Total score on this scale ranges from 0 (no signs of disability) to 10 (most severe disability score) and the upper-limb subscore ranges from 0 to 5.
Throughout the study, safety was evaluated by assessing the occurrence of adverse events (AEs) and their relationship to the product. A physical examination was performed and vital signs, biochemical, and haematological parameters were also monitored.
| Statistics
Sample size for the non-inferiority test comparing IqYmune ® and Kiovig ® was calculated based on the primary criterion of MMRC 10-sum score, assuming no difference between treatments. A difference ≤2 points in MMRC 10-sum score between the two products was considered not to be clinically meaningful. With a non-inferiority margin of 2, a within-participant error variance of 2.5, a one-tailed α risk of 2.5% and 90% power, 16 evaluable participants were required to achieve a lower confidence interval (CI) boundary ≥−2 for the The non-inferiority of IqYmune ® relative to Kiovig ® was assessed in one-tailed tests with a nominal α risk of 2.5%. Non-inferiority was considered to be demonstrated if the lower limit of the 95% CI of the
The total treated set (TTS) was defined as all subjects receiving at least one dose of product. The modified intent-to-treat (mITT) population was defined as all randomised subjects receiving at least one administration of product, for whom a baseline level and at least one post-treatment MMRC efficacy assessment were available. The per protocol set (PPS) was defined as all subjects from the mITT population completing the protocol without deviation (as assessed during the protocol deviation review meeting before unblinding) likely to affect the statistical analysis.
For efficacy evaluations, the mITT population was used for the primary analysis and the per-protocol set was used for the secondary analysis. Sensitivity analyses were also performed on these populations.
The TTS was defined as all subjects who received at least one dose of investigated medicinal product. The TTS was used for all safety analyses.
3 | RESULTS
| Participant characteristics and treatment
Between October 2013 and July 2015, 30 participants were screened, and 23 participants were randomised to sequence A (Kiovig ® then summarising the distribution of the participants is provided in Figure 1 .
The baseline characteristics of the patients were similar in the two groups ( 
| Efficacy
Sensitivity analysis and analysis of efficacy endpoints were performed on the mITT and PPS populations (Figure 1 ). 
|

| Secondary efficacy criteria
Using the same linear-mixed model as for the primary endpoint, no statistically significant difference between IqYmune ® and Kiovig ® was detected for the MMRC new 10-sum score, the Rasch-built MMRC 10-sum score, the MMRC 14-sum score, total INCAT disability score or normalised grip strength measured during the evaluation period (Table 4 ). The improvement in clinical global impression (CGI) measured at the end of each period was also similar for the two products, with no specific change observed in more than half of the participants (Table 5 ).
| Safety
The population used for the evaluation of safety consisted of the 22 participants who received at least one infusion of product. Participant exposure levels were similar for IqYmune ® and Kiovig ® (Table 6 ).
Both products were well-tolerated. (Table 7) . The most common AEs were headache and fatigue, for both products (Table 7) . One participant had a single episode of severe headache attributed to IqYmune ® ; this episode lasted 2 days and resolved with medication without sequelae. The non-inferiority margin of two points for MMRC 10-sum score mean between the two products was considered adequate. MMN is a rare, slowly progressing disease. A crossover design was also considered appropriate for this study. One weakness of crossover trials is the carryover effect across periods. The 12 weeks during which no assessments were made at the start of each period were considered to constitute an adequate wash-out phase to prevent carryover effects from previous IVIg treatment.
The non-inferiority of IqYmune Muscle/grip strength and weakness were assessed with scales previously used in other trials in participants with immune neuropathies 12 and MMN. 7 The use of the MMRC 10-sum score for assessing muscle strength in MMN was approved by the European Medicines Agency Table S1 ).
IVIg has been proven to improve weakness and disability in patients with MMN and is the gold standard treatment of this disabling disease. However, the effect of IVIg on motor symptoms and signs may decline after several years. 4 Consequently, other therapeutic options are being investigated. Subcutaneous immunoglobulin has been tested in small studies in MMN [14] [15] [16] [17] ; although maintenance was not obtained in all subjects, this option could be more convenient for some patients, as for chronic inflammatory demyelinating polyneuropathy. 18 The addition of eculizumab, which neutralises human complement C5, to IVIg in one small-controlled trial showed a trend towards improvement 19 which needs to be confirmed in larger studies.
This study was limited by the lack of high-quality outcome measures covering all the domains of disability, impairment, and quality of life in MMN. 20 The outcome measures used in MMN trials still lack standardisation and sensitivity. 21 At the time the protocol for this trial was designed, there was no validated functional disability scale for MMN. The Rasch-built overall disability scale for MMN (MMN-RODS) does overcome the shortcomings of ordinal scales was proposed in 2015 22 but still needs to be validated in new series.
In summary, IqYmune ® was not inferior to Kiovig ® in efficacy for the maintenance treatment of MMN. Safety results for both products were consistent with the known safety profile of IVIg. This IqYmune ® is a valid option for the maintenance treatment of MMN. The data shown are the numbers of AEs occurring (number and percentage of participants).
